ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Abstract Number: 0023

Hypophosphatasia May Be Misdiagnosed as Fibromyalgia: A Single Center Experience
Abstract Number: 0024

An International Delphi Consensus on Non-pharmacological Interventions for Fibromyalgia
Abstract Number: 0025

Clinical and Psychological Assessment of Rheumatoid Arthritis Patients with Fibromyalgia: A Real World Study
Abstract Number: 0026

A Modified Version of the 2016 ACR Fibromyalgia Criteria Cognitive Items Results in Stronger Correlation Between Subjective and Objective Measures of Cognitive Impairment
Abstract Number: 0027

CYP2D6 Genotype and Reduced Codeine Analgesic Effect in Real-World Clinical Practice
Abstract Number: 0028

Pain in the Time of Corona: Impact of COVID 19 Outbreak on Fibromyalgia Patients
Abstract Number: 0029

Urine Proteomic Classifiers Predict Renal Histological Activity and Chronicity Indices and May Predict Treatment Response in Lupus Nephritis
Abstract Number: 0030

Distinct DNA Methylation Patterns of Rheumatoid Arthritis Peripheral Blood and Synovial Tissue T Cells
Abstract Number: 0031

Metabolomics Profiling Predicts Outcome of Tocilizumab in Rheumatoid Arthritis
Abstract Number: 0032

A Prospective, Multicenter, Clinical Performance Evaluation Study for an in-vitro Diagnostics Medical Device (PREDYSTIC® Infliximab RA) for Prediction of Infliximab Responsiveness in the Treatment of Rheumatoid Arthritis
Abstract Number: 0033

Pre-pregnancy Long Non-coding RNA Expression Signatures Among Women with Rheumatoid Arthritis Who Improve or Worsen During Pregnancy
Abstract Number: 0034

Gene Expression Signatures in C-Reactive Protein High and Low Rheumatoid Arthritis
Abstract Number: 0035

Distinct Biological Pathways in Both Blood and Kidney Further Define Molecular Profiles Across Diverse Nephritides
Abstract Number: 0036

Molecular Phenotyping of Late-Stage Knee Osteoarthritis Synovium Through Total RNA-Sequencing
Abstract Number: 0037

Lipoprotein-associated Phospholipase A2: A New Biomarker for Lymphoma Development in Sjögren’s Syndrome

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].